Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNCs for Acute Traumatic Spinal Cord Injury
NCT04528550Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow-derived mononuclear cell in traumatic spinal cord injury (SCI), sponsored by Shanghai Changzheng Hospital. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
traumatic spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04528550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528550.